- The development of Immuno-Therapy in Medical Oncology has been practice changing for several frequent tumour types and established Immunotherapy as an additional class of therapeutics.
- Patient selection based of immune biomarkers may be associated with efficacy (predictive factor) but still remains controversial and other biomarkers could help in patient selection.
- The mechanism of action of Immune Check Point Inhibitors differs greatly from conventional cancer treatment and efficacy evaluation needs to be adapted.
- The systemic manipulation of the Immune system has proven efficacy against cancer cells but may also been associated with alteration of normal tissues or organs, targeted by Immune Check Point Inhibitors and consequently auto-immune or auto-immune-like side effects have been reported.
Download the programme
The programme of this event has been accredited with 10 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
John B.A.G. Haanen, Netherlands
Martin Reck, Germany